Investigating new medications for cannabis use disorder.
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).
This study is looking for new medications to help people with cannabis use disorder by boosting natural chemicals in the brain that might ease withdrawal symptoms, and if you're interested, you could participate in trials to see how well these new treatments work and how safe they are.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Makscientific, LLC NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project ID | NIH-10577008 on NIH RePORTER |
What this research studies
This research focuses on developing new medications for cannabis use disorder (CUD) by targeting specific enzymes in the brain that affect cannabinoid levels. The approach involves inhibiting fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) to increase the levels of natural cannabinoids, which may help alleviate withdrawal symptoms associated with cannabis use. The study builds on preliminary findings that suggest a combination of these inhibitors can produce effects similar to THC without the adverse effects of traditional treatments. Patients may be involved in trials to assess the effectiveness and safety of these new medications.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals struggling with cannabis use disorder who are seeking alternative treatment options.
Not a fit: Patients who do not have cannabis use disorder or those who are not interested in pharmacological treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective medications that help individuals manage cannabis use disorder without the negative side effects of current treatments.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance cannabinoid activity, indicating potential for success in this area.
Where this research is happening
Burlington, United States
- Makscientific, LLC — Burlington, United States (Active)
Researchers
- Principal investigator: Alapafuja, Shakiru Olajire — Makscientific, LLC
- Study coordinator: Alapafuja, Shakiru Olajire
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.